Trial Profile
Biomarkers of gemcitabine and erlotinib treatment in advanced pancreatic cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Dec 2015
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Gemcitabine (Primary)
- Indications Pancreatic cancer
- Focus Biomarker; Therapeutic Use
- 10 Dec 2015 New trial record